COMMUNIQUÉS West-GlobeNewswire

PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES
15/10/2026
MINNEAPOLIS, MN, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV) (“PetVivo” or the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo [...]
First Tracks Biotherapeutics Announces $200 Million Private Placement
15/10/2026
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
15/10/2026
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing [...]
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
15/10/2026
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding [...]
Claris Biotherapeutics to Host Virtual KOL Event on Positive CSB-001 Data and the Unmet Need in Limbal Stem Cell Deficiency (LSCD)
15/10/2026
SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where limited or no [...]
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
15/10/2026
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment- [...]
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026
October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to [...]
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026
MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control Phase 1b ‘MTX325-101’ study – taking place [...]
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15/10/2026
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization Appointment comes as iOnctura prepares for late-stage [...]
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026
Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery [...]
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology
15/10/2026
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through [...]
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
15/10/2026
Nantes, France, October 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and [...]
OSE Immunotherapeutics présentera lors de la 10ème Chardan Annual Healthcare Conference
15/10/2026
Nantes, France, 15 octobre 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo: OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
15/10/2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, [...]
IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems
15/10/2026
IBA is preferred supplier for a 12-system national PET radiopharmaceutical production network, securing capacity ahead of demand across diagnostics and theranostics Louvain-la-Neuve, Belgium – October 15, 2026, 7 a.m [...]
IBA sélectionnée pour équiper l’expansion aux États-Unis d’un leader de la production de radiopharmaceutiques avec une commande de 12 systèmes Cyclone® KIUBE
15/10/2026
IBA devient le fournisseur privilégié pour équiper de 12 systèmes un réseau national de production de radiopharmaceutiques TEP, sécurisant des capacités de production en anticipation de la demande dans les domaines du [...]
Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026
15/10/2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases 2026 annual guidance The company reports 40% year-over-year increase in sales in the first nine months of 2026 Schlieren ( [...]
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
15/10/2026
Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 Expected year-over-year growth of approximately 15 [...]
EC-Council Releases ADG 2.0 and Offers Its AI Governance Crosswalks Free to Every Government, Regulator and Standards Body as Nations Split on AI Rules
15/10/2026
With autonomous no global treaty in sight, EC-Council will assist any public authority that asks to map ADG 2.0's 180+ controls to its own laws and standards Photo Courtesy of EC-Council TAMPA, Fla., Oct. 14, 2026 ( [...]

Pages